Abstract 920: Characterization of the orthotopic MMTV PyMT murine mammary carcinoma model following radiation and immune checkpoint blockade

2020 ◽  
Author(s):  
Erin E. Trachet ◽  
Derrik Germain Germain ◽  
Sumithra Urs ◽  
David Draper ◽  
Maryland Rosenfeld Franklin
Keyword(s):  
Mammary Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Model Following ◽  
Murine Mammary Carcinoma

scholarly journals P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC

2018 ◽  
Vol 13 (10) ◽  
pp. S738
Author(s):  
M. Altan ◽  
M. Toki ◽  
D. Carvajal-Hausdorf ◽  
S. Gettinger ◽  
R. Herbst ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

scholarly journals Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model

2020 ◽  
Vol 10 ◽  
Author(s):  
Evelyn Sirait-Fischer ◽  
Catherine Olesch ◽  
Annika F. Fink ◽  
Matthias Berkefeld ◽  
Arnaud Huard ◽  
...  
Keyword(s):  
Mouse Model ◽  
Mammary Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

Abstract 870: Derivation and characterization of antibodies from immune checkpoint blockade treated cancer patients

2016 ◽  
Author(s):  
Mark Branum ◽  
Laura Smith ◽  
Heather Brett ◽  
Paul Algate ◽  
Brad Greenfield ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade

scholarly journals Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade

2021 ◽  
Author(s):  
Elizabeth I. Buchbinder ◽  
Jason L. Weirather ◽  
Michael Manos ◽  
Brian J. Quattrochi ◽  
Lynette M. Sholl ◽  
...  
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Mucosal Melanoma ◽  
Checkpoint Blockade

scholarly journals Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Chi Yan ◽  
Ann Richmond
Keyword(s):  
Immune Checkpoint ◽  
Tumor Response ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Type I ◽  
List Type ◽  
Cancer Types ◽  
Pan Cancer ◽  
Cancer Bioinformatics

Highlights CD40 expression correlates with the type I anti-tumor response and better survival. Pan-cancer bioinformatics characterization reveals reduced CD40 expression in 11 cancer types, including RASmut melanoma compared to nevi. RAS mutation correlates with reduced CD40 expression in malignant melanoma. CD40 expression is associated with better response to immune checkpoint blockade therapy in melanoma.

Analysis of Advanced Melanomas Changed from Immune Checkpoint Blockade Therapy to Palliative Care

2018 ◽  
Vol 80 (1) ◽  
pp. 51-55
Author(s):  
Ai KAJITA ◽  
Osamu YAMASAKI ◽  
Tatsuya KAJI ◽  
Hiroshi UMEMURA ◽  
Keiji IWATSUKI
Keyword(s):  
Palliative Care ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade
Sign in / Sign up

Export Citation Format

Share Document